Pharmaceutical Report Library l Report Store l Pharma Intelligence

Schizophrenia and Bipolar Disorder Payer Interview – US, South

This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning schizophrenia and bipolar disorder, with a focus on oral antipsychotics and long-acting injectables.

April 28, 2021

Find out more

Schizophrenia and Bipolar Disorder KOL Interview – US, Southeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

April 28, 2021

Find out more

Schizophrenia and Bipolar Disorder KOL Interview – US, Northeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

April 28, 2021

Find out more

Schizophrenia and Bipolar Disorder KOL Interview – US, East Coast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

April 28, 2021

Find out more

Schizophrenia and Bipolar Disorder KOL Interview – Germany

$599.00

This interview with an EU-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

April 28, 2021

Find out more

Respiratory Care: Mechanical Ventilators and Pulmonary Function Testing Systems

$4,750.00

Asthma and COPD affect an estimated 590 million people worldwide, with an additional 114 million affected by COVID-19 from March 2020 to March 2021. Devices used in the diagnosis and treatment of these and other respiratory disorders include mechanical ventilators and pulmonary function testing systems.

March 30, 2021

Find out more

Chronic Lymphocytic Leukemia (CLL) KOL Interview – US

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Key pipeline assets highlighted include the CAR-T therapy Breyanzi, reversible BTK inhibitors MK-1026 and pirtobrutinib, and the PI3K inhibitor TG-1303.

October 1, 2020

Find out more

Diabetes Management: Blood Glucose Monitoring Devices Market (2021)

$4,750.00

This report provides a detailed presentation of diabetes and blood glucose monitoring devices, including standard fingerstick-based blood glucose meters (BGMs) and new sensor-based continuous glucose monitoring systems (CGMs) that attach to the body and monitor blood glucose 24 hours a day

March 31, 2021

Find out more

Arthroscopy Products and Sports Medicine Fixation Implants (2021)

$4,750.00

This Meddevicetracker report provides an analysis of the market for arthroscopy products (including visualization systems, fluid management equipment, and manual and powered instruments) and sports medicine/soft tissue fixation implants for the US, five major EU markets, Japan, and the rest of the world.

March 18, 2021

Find out more

Depression KOL Interview – US #2

$599.00

A US expert in the depression field dives into the treatment algorithm, critical unmet needs, and pipeline drugs such as SAGE-217 and AXS-05.

March 2, 2021

Find out more

Depression KOL Interview – US #1

$599.00

A US expert in the depression field dives into the treatment algorithm, critical unmet needs, and pipeline drugs such as SAGE-217 and AXS-05.

March 2, 2021

Find out more

Ulcerative Colitis (UC) KOL Interview – UK

$599.00

A UK expert in the ulcerative colitis (UC) field dives into the treatment algorithm, critical unmet needs, and pipeline drugs, such as the Janus kinase inhibitors and sphingosine 1-phosphate (S1P) modulators.

March 1, 2021

Find out more

Inflammatory Bowel Disease (IBD) KOL Interview – US

$599.00

A US gastroenterology expert dives into the treatment algorithm, critical unmet needs, and pipeline drugs for IBD, such as the Janus kinase inhibitors and sphingosine 1-phosphate (S1P) modulators.

March 1, 2021

Find out more

Biomedtracker Early 2021 Outlook Report

$4,750.00

In this report, we cover catalysts from 28 drugs, devices, diagnostics, and deals expected to occur in early 2021. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.

February 1, 2021

Find out more

Market Spotlight: Thyroid Eye Disease (TED)

$1,318.00

Thyroid eye disease (TED), also called Graves’ ophthalmopathy or orbitopathy, is an autoimmune disorder that causes inflammation in the orbital and retroocular tissues. It generally occurs as a manifestation of Graves’ disease, a condition in which the immune system attacks the thyroid gland, commonly affecting the eyes and skin. Although TED is usually found in Graves’ hyperthyroidism patients, some patients may have autoimmune euthyroid or hypothyroid thyroiditis. TED is mostly a mild, non-progressive, and self-limiting disease; however, in rare cases it can progress to vision loss. The negative impact of TED on the social and psychological well-being of individuals is an established consequence of the disease.

March 17, 2022

Find out more

Market Spotlight: Glioblastoma (GBM)

$1,318.00

This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

April 14, 2022

Find out more

Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP)

Despite Truvada’s and Descovy’s commercial success, PrEP remains underutilized due to poor awareness and lack of/limited reimbursement in some European countries, though uptake is increasing due to recent favorable reimbursement decisions in Germany, Spain, England, Wales, and Northern Ireland, as well as due to Gilead’s marketing efforts. The US has the highest rate of uptake (estimated at 22% of at-risk individuals in 2020) and generates the majority of global PrEP revenues.

March 23, 2022

Find out more

Disease Analysis: HIV Treatment

The HIV treatment market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand through to 2025, driven primarily by increases in disease prevalence and continued uptake of Gilead’s Biktarvy and ViiV Healthcare’s portfolio of two-drug regimens. However, a plethora of products undergoing patent expiry across the forecast period will tip the market into decline from 2026.

February 4, 2022

Find out more

Diabetes Management: Insulin Pumps Market (2020)

$4,750.00

This report provides an overview of diabetes, automated insulin pump systems, and a comprehensive market and competitive analysis.

December 30, 2020

Find out more

Respiratory Care: Noninvasive Ventilation and Airway Management Products

$4,750.00

Asthma and COPD, the two most prevalent respiratory diseases, affect nearly 600 million people worldwide, with annual mortality rates exceeding 3 million for COPD and 400,000 for asthma. COVID-19 has infected more than 60 million people worldwide, resulting in 1.5 million deaths. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the positive airway pressure (PAP)-based noninvasive ventilation (NIV) and airway management products market, including CPAP and BiPAP devices as well as heat/moisture exchangers (HMEs), humidifiers, and nebulizers (including large- and small-volume nebulizers and nebulizer compressors).

December 17, 2020

Find out more

Extremity Replacement Implants

$4,750.00

This medical market and technology report provides a comprehensive discussion of the global market for extremities replacement implants. Market forecasts and competitive analyses are provided for the shoulder, elbow, ankle, and small joint arthroplasty devices markets. Geographic segments covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets, which includes all other countries.

December 21, 2020

Find out more

Disease Analysis: COVID-19 Prevention

COVID-19 is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that emerged in late 2019 in Wuhan, China. As of October 2021, there have been 245,373,039 confirmed cases of COVID-19, and 4,979,421 deaths globally. SARS-CoV-2 belongs to the coronavirus family, which collectively cause respiratory and intestinal disease in humans and animals, with other prominent members of the family including Middle East respiratory syndrome (MERS) virus and severe acute respiratory syndrome (SARS) virus.

May 17, 2022

Find out more

Disease Analysis: COVID-19 Treatment

COVID-19 is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that emerged in late 2019 in Wuhan, China. As of 12 March 2021, there have been 117,799,584 confirmed cases of COVID-19, and 2,615,018 confirmed deaths globally. SARS-CoV-2 belongs to the coronavirus family, which collectively cause respiratory and intestinal disease in humans and animals, with other prominent members of the family including Middle East respiratory syndrome (MERS) virus and severe acute respiratory syndrome (SARS) virus. SARS-CoV-2 is believed to have originated from a horseshoe bat coronavirus, which either spread to humans directly or jumped via an intermediate host (possibly a pangolin), which may have facilitated transmission to humans.

November 1, 2021

Find out more

Knee Replacement Implants Market

$4,750.00

This medical market and technology report provides a comprehensive discussion of the global market for knee replacement implants. Markets covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets, which includes all other countries.

November 18, 2020

Find out more

Melanoma KOL Interview – US #1

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for melanoma. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include lifileucel, seviprotimut-L, Lenvima, and TAVO.

February 25, 2022

Find out more

Prostate Cancer KOL Interview – US

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Diagnostic testing and unmet needs are also discussed. Key pipeline assets highlighted include Keytruda, Tecentriq, ipatasertib, DCVAC/PCa, capivasertib, Lutetium 177Lu-PSMA-617, and Cabometyx.

November 10, 2020

Find out more

Colorectal Cancer KOL Interview – US

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for colorectal cancer. Disease stratifications by staging and expression profile of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Keytruda, Braftovi, Opdivo, Avastin (and bevacizumab biosimilars), Herceptin (and trastuzumab biosimilars), Lonsurf, and Erbitux.

October 29, 2020

Find out more

2020 Post-ESMO Report

$4,750.00

The Annual European Society for Medical Oncology (ESMO) 2020 Congress was held virtually from September 19 to September 21, 2020 due to the COVID-19 pandemic.

October 5, 2020

Find out more

Neurointervention: Mechanical Thrombectomy Devices Market

$4,750.00

This medical market and technology report provides a comprehensive discussion of the global market for neurointerventional cerebral aneurysm and arteriovenous malformation (AVM) embolization systems.

October 30, 2020

Find out more

Datamonitor Healthcare Infectious Diseases Disease Analysis: Seasonal Influenza Vaccines

$599.00

The seasonal influenza vaccines market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand over the next 10 years, largely due to the continued uptake of premium-priced vaccines in the elderly subgroup, including quadrivalent forms of Fluzone High-Dose (HD) and Fluad, as well as the launch of the first-in-class adjuvanted nanoparticle vaccine, NanoFlu.

October 30, 2020

Find out more

Hip Replacement Implants Market

$4,750.00

An aging global population and increasing life expectancy are driving growth in the global market for hip replacement implants. This market is expected to grow at a CAGR of 2.1% over the forecast period, reaching a value of nearly $7bn in the year 2024.

October 22, 2020

Find out more

Biomedtracker Q4 2020 Outlook Report

$4,750.00

In this report, we cover catalysts from 35 drugs, devices, diagnostics, and deals expected to occur in Q4 2020. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.

October 9, 2020

Find out more

Molecular Diagnostics Market

$4,750.00

Molecular diagnostics is being applied to an increasingly wide range of applications in infectious disease, oncology, and genetic disease diagnosis and screening and to a number of emerging applications in other diseases. The global market for molecular diagnostics is expected to grow at a CAGR of 10.8% between 2019 and 2024, reaching a value of more than $12bn.

September 30, 2020

Find out more

Multiple Myeloma KOL Interview – US

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and critical unmet needs are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.

May 15, 2020

Find out more

Multiple Myeloma KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and UK market access issues are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.

May 15, 2020

Find out more

Market Spotlight: Lysosomal Storage Disorders

$1,318.00

This Market Spotlight report covers the Lysosomal Storage Disorders market, comprising epidemiology, key marketed and pipeline drugs, recent events and analyst opinion, key regulatory events, licensing and asset deals, probability of success, and clinical trials.

April 28, 2022

Find out more

Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Northeast

$599.00

Key topics discussed in this specialist interview with a US-based key opinion leader (KOL) include the diagnostic landscape in NASH and future market trends, with a focus on GLP-1 agonists, FGF 19/21 analogs, and FXR agonists.

August 28, 2020

Find out more

Disease Analysis: Respiratory Syncytial Virus (RSV) Prevention

Respiratory syncytial virus (RSV), a member of the Paramyxoviridae family, is an enveloped, non-segmented, single-stranded, negativesense RNA virus. It is a common respiratory virus that is the leading cause of bronchiolitis in infants, and is estimated to be responsible for 22% of all episodes of acute lower respiratory tract infections in young children.

March 25, 2022

Find out more

Spinal Fusion: Implanted Instrumentation

$4,750.00

Sales of implanted instrumentation for spinal fusion procedures totaled approximately $4.4bn in 2019, with sales expected to climb at a CAGR of 2.2% through 2024. Growth in the spinal fusion instrumentation market is being driven by several factors including the prevalence of degenerative disc disease, new surgical techniques and associated instrumentation that have expanded the range of product indications, and the launch of new enabling technology such as diagnostic, nerve monitoring, and navigation systems (including robotic-assisted surgery).

August 20, 2020

Find out more

Drug Delivery: Infusion Devices – August 2020

$4,750.00

This report provides a discussion of current/forecast markets, competitors, and opportunities in the global infusion drug delivery devices market, including the volumetric, syringe, ambulatory, disposable, implantable, and enteral pumps segments. Geographic regions covered include the US, five major European markets, Japan, and Rest of World markets; the forecast period is from 2019–24.

August 14, 2020

Find out more

Neuromodulation: Spinal Cord Stimulation Devices Market

$4,750.00

According to a recent CDC study, 20.1% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities with similar numbers being reported in Europe. In 2021, the spinal cord stimulation (SCS) devices market was worth nearly $2.9 bn. Market drivers of the SCS devices market through 2026 will be driven by an aging population and an increase in selected conditions (eg back/leg pain, and a growing number of indications) that result in debilitating and unrelenting chronic pain.

February 22, 2022

Find out more

Biomedtracker / Meddevicetracker Q3 2020 Outlook Report

$4,750.00

In this report, we cover catalysts from 27 drugs, devices, diagnostics and deals expected to occur in Q3 2020. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

July 1, 2020

Find out more

Gastric Cancer KOL Interview – US

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for gastric cancer. Disease stratifications by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Opdivo, Yervoy, Keytruda, Cyramza, Herceptin, and Enhertu.

August 5, 2020

Find out more

Disease Analysis: Wet Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the progressive degradation of the part of the eye responsible for visual acuity, causing a loss of central vision. AMD is the leading cause of blindness in individuals who are over 65 years old. As the chances of experiencing any form of AMD increase with age, treatment of this disease is becoming even more important as life expectancies continue to rise in most regions.

January 27, 2022

Find out more

Market Spotlight: Ischemic Stroke

$1,318.00

This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

February 18, 2022

Find out more

Report library

Schizophrenia and Bipolar Disorder Payer Interview – US, South

Schizophrenia and Bipolar Disorder KOL Interview – US, Southeast

Schizophrenia and Bipolar Disorder KOL Interview – US, Northeast

Schizophrenia and Bipolar Disorder KOL Interview – US, East Coast

Schizophrenia and Bipolar Disorder KOL Interview – Germany

Respiratory Care: Mechanical Ventilators and Pulmonary Function Testing Systems

Chronic Lymphocytic Leukemia (CLL) KOL Interview – US

Diabetes Management: Blood Glucose Monitoring Devices Market (2021)

Arthroscopy Products and Sports Medicine Fixation Implants (2021)

Depression KOL Interview – US #2

Depression KOL Interview – US #1

Ulcerative Colitis (UC) KOL Interview – UK

Inflammatory Bowel Disease (IBD) KOL Interview – US

Biomedtracker Early 2021 Outlook Report

Market Spotlight: Thyroid Eye Disease (TED)

Market Spotlight: Glioblastoma (GBM)

Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP)

Disease Analysis: HIV Treatment

Diabetes Management: Insulin Pumps Market (2020)

Respiratory Care: Noninvasive Ventilation and Airway Management Products

Extremity Replacement Implants

Disease Analysis: COVID-19 Prevention

Disease Analysis: COVID-19 Treatment

Knee Replacement Implants Market

Melanoma KOL Interview – US #1

Prostate Cancer KOL Interview – US

Colorectal Cancer KOL Interview – US

2020 Post-ESMO Report

Neurointervention: Mechanical Thrombectomy Devices Market

Datamonitor Healthcare Infectious Diseases Disease Analysis: Seasonal Influenza Vaccines

Hip Replacement Implants Market

Biomedtracker Q4 2020 Outlook Report

Molecular Diagnostics Market

Multiple Myeloma KOL Interview – US

Multiple Myeloma KOL Interview – UK

Market Spotlight: Lysosomal Storage Disorders

Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Northeast

Disease Analysis: Respiratory Syncytial Virus (RSV) Prevention

Spinal Fusion: Implanted Instrumentation

Drug Delivery: Infusion Devices – August 2020

Neuromodulation: Spinal Cord Stimulation Devices Market

Biomedtracker / Meddevicetracker Q3 2020 Outlook Report

Gastric Cancer KOL Interview – US

Disease Analysis: Wet Age-Related Macular Degeneration

Market Spotlight: Ischemic Stroke